Dino Mehic: Can Global Coagulation Testing Detect Abnormalities in BDUC?
Dino Mehic, Physician Scientist at the Medical University of Vienna, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Can global coagulation testing detect abnormalities in BDUC?
Bleeding disorder of unknown cause (BDUC) remains one of the most common diagnoses in patients with a lifelong bleeding tendency, yet routine laboratory testing is normal and objective biomarkers are lacking.
In our study of 464 BDUC patients from the Vienna Bleeding Biobank and 100 healthy controls, we evaluated non-activated whole-blood viscoelastic testing (ROTEM) to determine whether global assays capture hemostatic alterations.
Key findings:
- BDUC patients showed delayed clot formation and reduced maximum lysis resulting in an impaired overall clot formation profile.
- ROTEM parameters discriminated BDUC patients from healthy controls with good performance (ROC-AUC up to 0.81 using machine-learning models).
- Hemoglobin was the strongest determinant of ROTEM variability among clinical and laboratory parameters.
- However, ROTEM parameters did not correlate with bleeding severity, highlighting the complexity of bleeding phenotypes in BDUC.
Take-home: Global viscoelastic testing reveals detectable but modest alterations in clot formation in BDUC, yet these changes do not explain bleeding severity.
The search for robust biomarkers and underlying mechanism in BDUC therefore continues.
Grateful to all collaborators and the Vienna Bleeding Biobank team: Johanna Gebhart, Cihan Ay, Alice Assinger, Bernd Jilma, Maximilian Koeller.”
Title: Abnormal whole-blood viscoelastic testing in patients with bleeding disorder of unknown cause
Authors: Dino Mehic, Tim Dreier, Maximilian C. Koeller, Justin Oosterlee, Christa Drucker, Alice Assinger, Bernd Jilma, Cihan Ay, Ingrid Pabinger, Johanna Gebhart
Read the Full Article on Blood Vessels, Thrombosis and Hemostasis.

Other articles featuring Dino Mehic on Hemostasis Today.
-
Mar 4, 2026, 15:52Manik Madaan: Understanding 4 Hereditary Clotting Disorders
-
Mar 4, 2026, 15:46Samwel Mikaye։ Key Insights on Stroke Types, Diagnosis, and Management
-
Mar 4, 2026, 15:39Lu (Maggie) Qian: How Adaptive Trial Design Reveals Treatment Effects in COVID-19
-
Mar 4, 2026, 15:30Pall T. Onundarson: Risks of Switching Warfarin to DOACs in Frail Elderly Patients with NVAF
-
Mar 4, 2026, 15:25Mital Jhaveri: Key Updates in the 2026 Guideline on Acute Pulmonary Embolism in Adults
-
Mar 4, 2026, 15:14Jean Terrier: The Relationship Between DOAC Plasma Concentrations and Clinical Outcomes
-
Mar 4, 2026, 15:11Rishiraj Sinha: Why Trust Matters More Than Knowledge in Blood Donor Engagement
-
Mar 4, 2026, 15:08Nico Gagelmann: Honored to Receive the Young European Hematology Association Award
-
Mar 4, 2026, 14:45Rafael Demarchi Malgor: New Clinical Practice Guideline on Upper Extremity Deep Venous Thrombosis